Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031717967> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W3031717967 endingPage "412" @default.
- W3031717967 startingPage "409" @default.
- W3031717967 abstract "ObjectiveTo explore the efficacy and feasibility of idarubicin combined with medium-dose arabinoside in intensive chemotherapy for acute myeloid leukemia(AML).MethodsFifty remittent patients with induced chemotherapy who underwent the intensive consolidation therapy with medium-dose arabinoside from January 2010 to January 2015 in hematology department of General Hospital of Beijing Military Area were considered as the treatment group. The single arabinoside (2 g/m2, 1/12 h, d1-3) treatment for 50 cases in the same period were considered as the control group. Two groups were performed with 6 courses sequential. There were 28 males, 22 females in the treatment group, and average age was 27.6 years (18-52 years), with 3 cases of M1, 27 cases of M2, 8 cases of M4, 12 cases of M5. In the control group, there were 30 males, 20 females, and average age was 26.8 years (16-50 years), with 2 cases of M1, 30 cases of M2, 8 cases of M4, 10 cases of M5. Then the complications and disease-free survival of two groups were observed respectively.ResultsFollow-up was done until June 2015. In the treatment group, 1 case died of pulmonary infection, 2 cases died of septic shock and 3 cases died of pulmonary infection, 1 case died of septic shock in the control group. The treatment related mortality of both groups were 6% (3/50), 8% (4/50), the related relapse rates were 32% (16/50), 52% (26/50), the disease-free survival rates were 62% (31/50), 40% (20/50) respectively in two groups.ConclusionCompared with the single arabinoside, the intensive consolidation therapy with medium-dose arabinoside and idarubicin for the treatment of AML has gained lower relapse rate and the related mortality, and the DFS rate has been improved significantly, which need further clinical application.Key words: Leukemia, myeloid, acute; Idarubicin; Arabinoside; Intensive consolidation therapy" @default.
- W3031717967 created "2020-06-05" @default.
- W3031717967 creator A5003012633 @default.
- W3031717967 creator A5031013005 @default.
- W3031717967 creator A5035168940 @default.
- W3031717967 creator A5059996528 @default.
- W3031717967 creator A5084553146 @default.
- W3031717967 date "2016-07-25" @default.
- W3031717967 modified "2023-09-24" @default.
- W3031717967 title "Effect of idarubicin combined with medium-dose arabinoside in intensive chemotherapy on the prognosis of acute myeloid leukemia" @default.
- W3031717967 doi "https://doi.org/10.3760/cma.j.issn.1009-9921.2016.07.007" @default.
- W3031717967 hasPublicationYear "2016" @default.
- W3031717967 type Work @default.
- W3031717967 sameAs 3031717967 @default.
- W3031717967 citedByCount "0" @default.
- W3031717967 crossrefType "journal-article" @default.
- W3031717967 hasAuthorship W3031717967A5003012633 @default.
- W3031717967 hasAuthorship W3031717967A5031013005 @default.
- W3031717967 hasAuthorship W3031717967A5035168940 @default.
- W3031717967 hasAuthorship W3031717967A5059996528 @default.
- W3031717967 hasAuthorship W3031717967A5084553146 @default.
- W3031717967 hasConcept C126322002 @default.
- W3031717967 hasConcept C141071460 @default.
- W3031717967 hasConcept C2776694085 @default.
- W3031717967 hasConcept C2777628635 @default.
- W3031717967 hasConcept C2778041864 @default.
- W3031717967 hasConcept C2778384902 @default.
- W3031717967 hasConcept C2778461978 @default.
- W3031717967 hasConcept C2778729363 @default.
- W3031717967 hasConcept C2779117419 @default.
- W3031717967 hasConcept C71924100 @default.
- W3031717967 hasConcept C90924648 @default.
- W3031717967 hasConceptScore W3031717967C126322002 @default.
- W3031717967 hasConceptScore W3031717967C141071460 @default.
- W3031717967 hasConceptScore W3031717967C2776694085 @default.
- W3031717967 hasConceptScore W3031717967C2777628635 @default.
- W3031717967 hasConceptScore W3031717967C2778041864 @default.
- W3031717967 hasConceptScore W3031717967C2778384902 @default.
- W3031717967 hasConceptScore W3031717967C2778461978 @default.
- W3031717967 hasConceptScore W3031717967C2778729363 @default.
- W3031717967 hasConceptScore W3031717967C2779117419 @default.
- W3031717967 hasConceptScore W3031717967C71924100 @default.
- W3031717967 hasConceptScore W3031717967C90924648 @default.
- W3031717967 hasIssue "7" @default.
- W3031717967 hasLocation W30317179671 @default.
- W3031717967 hasOpenAccess W3031717967 @default.
- W3031717967 hasPrimaryLocation W30317179671 @default.
- W3031717967 hasRelatedWork W2060998040 @default.
- W3031717967 hasRelatedWork W2112667410 @default.
- W3031717967 hasRelatedWork W2284341874 @default.
- W3031717967 hasRelatedWork W2359693374 @default.
- W3031717967 hasRelatedWork W2367661864 @default.
- W3031717967 hasRelatedWork W2397116401 @default.
- W3031717967 hasRelatedWork W2408401586 @default.
- W3031717967 hasRelatedWork W24153442 @default.
- W3031717967 hasRelatedWork W2471657327 @default.
- W3031717967 hasRelatedWork W2520448917 @default.
- W3031717967 hasRelatedWork W2547395346 @default.
- W3031717967 hasRelatedWork W2556913689 @default.
- W3031717967 hasRelatedWork W2556940920 @default.
- W3031717967 hasRelatedWork W2557237650 @default.
- W3031717967 hasRelatedWork W2559231919 @default.
- W3031717967 hasRelatedWork W2561786929 @default.
- W3031717967 hasRelatedWork W2588799177 @default.
- W3031717967 hasRelatedWork W3031253044 @default.
- W3031717967 hasRelatedWork W66165608 @default.
- W3031717967 hasRelatedWork W2189611065 @default.
- W3031717967 hasVolume "25" @default.
- W3031717967 isParatext "false" @default.
- W3031717967 isRetracted "false" @default.
- W3031717967 magId "3031717967" @default.
- W3031717967 workType "article" @default.